Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk

Successful acute myeloid leukemia (AML) induction chemotherapy reduces leukemic cells, restores normal hematopoiesis, and results in complete remission (CR) [1], which is associated with improved prognosis [2,3]. Many induction strategies exist, but for over 40 years the cytarabine/anthracycline regimen has been considered standard (so-called 7  + 3) [4]. The best outcomes occur in younger patients with adequate performance status and favorable risk leukemia. In contrast, older patients (≥60 years) and those with adverse prognostic markers fare poorly [5].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research